<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04990388</url>
  </required_header>
  <id_info>
    <org_study_id>UX053-CL101</org_study_id>
    <secondary_id>2021-000903-19</secondary_id>
    <nct_id>NCT04990388</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)</brief_title>
  <official_title>A Phase 1/2 First-in-human, 2-part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (Part 1: Open-label) and Repeat Doses (Part 2: Randomized, Double-blind, Placebo-controlled) of UX053 in Patients With GSD III</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ultragenyx Pharmaceutical Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ultragenyx Pharmaceutical Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the safety of UX053 in adults with Glycogen&#xD;
      Storage Disease Type III (GSD III).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a phase 1/2 first-in-human (FIH), 2-part study to evaluate the safety,&#xD;
      tolerability, and pharmacokinetic (PK) of a single ascending dose (SAD; part 1) and repeat&#xD;
      doses (RD; part 2) of UX053 in patients with GSD III. Single SAD and RD of UX053 are tested&#xD;
      in separate cohorts. The SAD cohorts will be open-label, while the RD dose cohorts will be&#xD;
      randomized, double-blind, and placebo-controlled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The SAD cohorts will be open-label, while the RD dose cohorts will be randomized, double-blind, and placebo-controlled.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of treatment-emergent adverse events (TEAEs), serious TEAEs, and related TEAEs in the SAD and RD Periods</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AGL mRNA: time of maximum observed concentration (Tmax)</measure>
    <time_frame>From pre-infusion up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AGL mRNA: maximum concentration (Cmax)</measure>
    <time_frame>From pre-infusion up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AGL mRNA: area under the concentration-time curve (AUC) from time 0 to the last measurable concentration (AUClast)</measure>
    <time_frame>From pre-infusion up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AGL mRNA: AUC from time 0 to infinity (AUCinf)</measure>
    <time_frame>From pre-infusion up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AGL mRNA: AUC from time 0 to end of dosing period (AUCtau; RD Period only)</measure>
    <time_frame>From pre-infusion up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AGL mRNA: accumulation ratio (calculated as AUC after repeat dose / AUC after a single dose; RAUC; RD Period only)</measure>
    <time_frame>From pre-infusion up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AGL mRNA: time of last measurable concentration (Tlast)</measure>
    <time_frame>From pre-infusion up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AGL mRNA: half life (T1/2)</measure>
    <time_frame>From pre-infusion up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AGL mRNA: clearance (CL)</measure>
    <time_frame>From pre-infusion up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of AGL mRNA: volume of distribution in a steady state (Vss; SAD Period only)</measure>
    <time_frame>From pre-infusion up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ATX95: Tmax</measure>
    <time_frame>From pre-infusion up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ATX95: Cmax</measure>
    <time_frame>From pre-infusion up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ATX95: AUClast</measure>
    <time_frame>From pre-infusion up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ATX95: AUCinf</measure>
    <time_frame>From pre-infusion up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ATX95: AUCtau; RD Period only</measure>
    <time_frame>From pre-infusion up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ATX95: accumulation ratio (calculated as AUC after repeat dose / AUC after a single dose; RAUC; RD Period only)</measure>
    <time_frame>From pre-infusion up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ATX95: Tlast</measure>
    <time_frame>From pre-infusion up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ATX95: T1/2</measure>
    <time_frame>From pre-infusion up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ATX95: CL</measure>
    <time_frame>From pre-infusion up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters of ATX95: Vss; SAD Period only</measure>
    <time_frame>From pre-infusion up to Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Glycogen Storage Disease Type III</condition>
  <arm_group>
    <arm_group_label>Stage 1: UX053 Dose Level 1S</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants to receive a single, peripheral intravenous (IV) infusion of UX053 plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: UX053 Dose Level 2S</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants to receive a single, peripheral IV infusion of UX053 plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: UX053 Dose Level 3S</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants to receive a single, peripheral IV infusion of UX053 plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1: UX053 Dose Level 4S</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants to receive a single, peripheral IV infusion of UX053 plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: UX053 Dose Level 1R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive a single, peripheral IV infusion of UX053 plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker every 2 weeks (Q2W) for 5 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: UX053 Dose Level 2R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive a single, peripheral IV infusion of UX053 plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker Q2W for 5 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: UX053 Dose Level 3R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive a single, peripheral IV infusion of UX053 plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker Q2W for 5 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: UX053 Dose Level 4R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive a single, peripheral IV infusion of UX053 plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker Q2W for 5 doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2: Placebo Dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomized to receive a single, peripheral IV infusions of matching placebo, plus premedication, consisting of oral paracetamol/acetaminophen or ibuprofen, an H2 blocker, and an H1 blocker Q2W for 5 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UX053</intervention_name>
    <description>mRNA-based biologic</description>
    <arm_group_label>Stage 1: UX053 Dose Level 1S</arm_group_label>
    <arm_group_label>Stage 1: UX053 Dose Level 2S</arm_group_label>
    <arm_group_label>Stage 1: UX053 Dose Level 3S</arm_group_label>
    <arm_group_label>Stage 1: UX053 Dose Level 4S</arm_group_label>
    <arm_group_label>Stage 2: UX053 Dose Level 1R</arm_group_label>
    <arm_group_label>Stage 2: UX053 Dose Level 2R</arm_group_label>
    <arm_group_label>Stage 2: UX053 Dose Level 3R</arm_group_label>
    <arm_group_label>Stage 2: UX053 Dose Level 4R</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>consists of the same components as the formulation buffer for UX053</description>
    <arm_group_label>Stage 2: Placebo Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antipyretic</intervention_name>
    <description>subjects will receive oral premedication prior to infusion</description>
    <arm_group_label>Stage 1: UX053 Dose Level 1S</arm_group_label>
    <arm_group_label>Stage 1: UX053 Dose Level 2S</arm_group_label>
    <arm_group_label>Stage 1: UX053 Dose Level 3S</arm_group_label>
    <arm_group_label>Stage 1: UX053 Dose Level 4S</arm_group_label>
    <arm_group_label>Stage 2: Placebo Dose</arm_group_label>
    <arm_group_label>Stage 2: UX053 Dose Level 1R</arm_group_label>
    <arm_group_label>Stage 2: UX053 Dose Level 2R</arm_group_label>
    <arm_group_label>Stage 2: UX053 Dose Level 3R</arm_group_label>
    <arm_group_label>Stage 2: UX053 Dose Level 4R</arm_group_label>
    <other_name>paracetamol</other_name>
    <other_name>acetaminophen</other_name>
    <other_name>ibuprofen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>H2 Blocker</intervention_name>
    <description>subjects will receive oral premedication prior to infusion</description>
    <arm_group_label>Stage 1: UX053 Dose Level 1S</arm_group_label>
    <arm_group_label>Stage 1: UX053 Dose Level 2S</arm_group_label>
    <arm_group_label>Stage 1: UX053 Dose Level 3S</arm_group_label>
    <arm_group_label>Stage 1: UX053 Dose Level 4S</arm_group_label>
    <arm_group_label>Stage 2: Placebo Dose</arm_group_label>
    <arm_group_label>Stage 2: UX053 Dose Level 1R</arm_group_label>
    <arm_group_label>Stage 2: UX053 Dose Level 2R</arm_group_label>
    <arm_group_label>Stage 2: UX053 Dose Level 3R</arm_group_label>
    <arm_group_label>Stage 2: UX053 Dose Level 4R</arm_group_label>
    <other_name>famotidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>H1 Blocker</intervention_name>
    <description>subjects will receive oral premedication prior to infusion</description>
    <arm_group_label>Stage 1: UX053 Dose Level 1S</arm_group_label>
    <arm_group_label>Stage 1: UX053 Dose Level 2S</arm_group_label>
    <arm_group_label>Stage 1: UX053 Dose Level 3S</arm_group_label>
    <arm_group_label>Stage 1: UX053 Dose Level 4S</arm_group_label>
    <arm_group_label>Stage 2: Placebo Dose</arm_group_label>
    <arm_group_label>Stage 2: UX053 Dose Level 1R</arm_group_label>
    <arm_group_label>Stage 2: UX053 Dose Level 2R</arm_group_label>
    <arm_group_label>Stage 2: UX053 Dose Level 3R</arm_group_label>
    <arm_group_label>Stage 2: UX053 Dose Level 4R</arm_group_label>
    <other_name>cetirizine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of GSD III by gene sequencing or enzymatic testing&#xD;
&#xD;
          -  History of significant hypoglycemia or elevation in liver enzyme (alanine&#xD;
             aminotransferase) in the past year&#xD;
&#xD;
          -  Alanine aminotransferase at or below 5 times normal during the three months prior to&#xD;
             dosing&#xD;
&#xD;
          -  Willing and able to comply with standard dietary management of GSD III&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  History of liver transplant or currently awaiting liver transplant&#xD;
&#xD;
          -  History of cirrhosis&#xD;
&#xD;
          -  Active Hepatitis B or C&#xD;
&#xD;
          -  Severe kidney impairment&#xD;
&#xD;
          -  History of liver cancer or large liver tumors&#xD;
&#xD;
          -  History of any cancer within the past 3 years&#xD;
&#xD;
          -  Known history of HIV infection&#xD;
&#xD;
          -  Known severe allergy to polyethylene glycol (PEG), polysorbate, or mRNA vaccine&#xD;
&#xD;
          -  Heart failure that causes marked limitation in physical activity&#xD;
&#xD;
          -  Poorly controlled diabetes&#xD;
&#xD;
          -  Poorly controlled hypothyroidism&#xD;
&#xD;
          -  Treatment with immunosuppressive medications such as those used to treat chronic&#xD;
             autoimmune conditions and solid organ transplants&#xD;
&#xD;
          -  Pregnant or nursing, or planning to become pregnant during the study&#xD;
&#xD;
        Note: Additional inclusion/exclusion criteria may apply, per protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Ultragenyx Pharmaceutical Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patients Contact: Trial Recruitment</last_name>
    <phone>1-888-756-8657</phone>
    <email>trialrecruitment@ultragenyx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>HCPs Contact: Medical Information</last_name>
    <phone>1-888-756-8657</phone>
    <email>medinfo@ultragenyx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bron</city>
        <state>Cedex</state>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clamart</city>
        <zip>92140</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salford</city>
        <state>Greater Manchester</state>
        <zip>M68HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 26, 2021</study_first_submitted>
  <study_first_submitted_qc>July 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycogen Storage Disease</mesh_term>
    <mesh_term>Glycogen Storage Disease Type III</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Antipyretics</mesh_term>
    <mesh_term>Cetirizine</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Famotidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

